1. Define context(s)
reveal new biological insights
Primary goal of the model/tool/database
Single-cell RNA sequencing (scRNA-seq) provides details for individual cells; however, crucial spatial information is often lost. We present SpaOTsc, a method relying on structured optimal transport to recover spatial properties of scRNA-seq data by utilizing spatial measurements of a relatively small number of genes. A spatial metric for individual cells in scRNA-seq data is first established based on a map connecting it with the spatial measurements. The cell–cell communications are then obtained by “optimally transporting” signal senders to target signal receivers in space. Using partial information decomposition, we next compute the intercellular gene–gene information flow to estimate the spatial regulations between genes across cells. Four datasets are employed for cross-validation of spatial gene expression prediction and comparison to known cell–cell communications. SpaOTsc has broader applications, both in integrating non-spatial single-cell measurements with spatial data, and directly in spatial single-cell transcriptomics data to reconstruct spatial cellular dynamics in tissues.
Biological domain of the model
scRNA-seq data of various tissues
Structure(s) of interest in the model
Spatial arrangement of scRNA-seq data, cell-cell communications
Spatial scales included in the model
cellular to tissue
Time scales included in the model
seconds to weeks
2. Data for building and validating the model
Data for building the model |
Published? |
Private? |
How is credibility checked? |
Current Conformance Level / Target Conformance Level |
in vitro (primary cells cell, lines, etc.) |
|
|
|
|
ex vivo (excised tissues) |
|
|
|
|
in vivo pre-clinical (lower-level organism or small animal) |
Yes |
No |
The model was built in an unsupervised way on unbiased single-cell RNA sequencing data and spatial data. |
Extensive |
in vivo pre-clinical (large animal) |
Yes |
No |
The model was built in an unsupervised way on unbiased single-cell RNA sequencing data and spatial data. |
Extensive |
Human subjects/clinical |
|
|
|
|
Other: ________________________ |
|
|
|
|
Data for validating the model |
Published? |
Private? |
How is credibility checked? |
Current Conformance Level / Target Conformance Level |
in vitro (primary cells cell, lines, etc.) |
|
|
|
|
ex vivo (excised tissues) |
|
|
|
|
in vivo pre-clinical (lower-level organism or small animal) |
Yes |
No |
Cross validation using spatial data. By comparing the model determined cell-cell communications to knowledge |
Adequate |
in vivo pre-clinical (large animal) |
Yes |
No |
Cross validation using spatial data. By comparing the model determined cell-cell communications to knowledge |
Adequate |
Human subjects/clinical |
|
|
|
|
Other: ________________________ |
|
|
|
|
3. Validate within context(s)
|
Who does it? |
When does it happen? |
How is it done? |
Current Conformance Level / Target Conformance Level |
Verification |
Postdocs/investigators |
Throughout the project |
1) The convergence of algorithm is guaranteed. 2) The computational results for projecting scRNA-seq data to space are consistent with expectations. |
Extensive |
Validation |
Postdocs/investigators |
As the unsupervised model was established |
1) The spatial projection of scRNA-seq data is cross-validated in predicting known spatial gene expression. 2) The inferred spatial origins of scRNA-seq data is validated by comparing to known spatial locations of specific cell types. 3) The inferred cell-cell communication networks agree with available knowledge. |
Extensive |
Uncertainty quantification |
|
|
|
|
Sensitivity analysis |
Postdocs/investigators |
As the unsupervised model was established |
By tuning key parameters and comparing to annotated data. |
Adequate |
Other:__________ |
|
|
|
|
Additional Comments |
|
|
|
|
4. Limitations
Disclaimer statement (explain key limitations) |
Who needs to know about this disclaimer? |
How is this disclaimer shared with that audience? |
Current Conformance Level / Target Conformance Level |
The technical noise of and the difference between single-cell RNA sequencing data and spatial data might cause inaccuracy. |
Scientific community who intends to apply this method to raw scRNA-seq data. |
In discussion of the paper. |
Adequate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5. Version control
Current Conformance Level / Target Conformance Level |
Extensive |
|
Naming Conventions? |
Repository? |
Code Review? |
individual modeler |
Yes |
Yes |
Peer |
within the lab |
Yes |
Yes |
Peer |
collaborators |
|
|
|
6. Documentation
|
Current Conformance Level / Target Conformance Level |
Code commented? |
Extensive |
Scope and intended use described? |
Extensive |
User’s guide? |
Extensive |
Developer’s guide? |
Partial |
7. Dissemination
Current Conformance Level / Target Conformance Level |
Extensive |
Target Audience(s): |
“Inner circle” |
Scientific community |
Public |
Simulations |
|
|
|
Models |
|
|
|
Software |
Python package: https://github.com/zcang/SpaOTsc |
Python package: https://github.com/zcang/SpaOTsc |
|
Results |
Shared folders |
Paper and tutorials |
|
Implications of results |
|
|
|
8. Independent reviews
Current Conformance Level / Target Conformance Level |
Insufficient |
Reviewer(s) name & affiliation: |
|
When was review performed? |
|
How was review performed and outcomes of the review? |
|
9. Test competing implementations
Current Conformance Level / Target Conformance Level |
Adequate |
|
Yes or No (briefly summarize) |
Were competing implementations tested? |
Yes. The method has been compared to several other commonly used methods on benchmark datasets. |
Did this lead to model refinement or improvement? |
No |